Colitis: Clinical Trials

133 trials for Colitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

133 completed. 133 Phase 3, 13 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3133Completed 133
Phase 213Completed 13

Follow Colitis: new trials by email Literature Review of Colitis trials Research Report on Colitis

Trials (filtered) newest first · largest first

All 133 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The Effects of Bromelain Supplement in Patients With Ulcerative Colitis
Bromlein, Placebo - Ulcerative Colitis, Primary Sclerosing Cholangitis
Phase 2 / Phase 3CompletedNational Nutrition and Food Technology Institute522024-04-202026-10-27
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis
Mirikizumab IV, Mirikizumab SC - Ulcerative Colitis
Phase 3CompletedEli Lilly and Company632023-11-222026-06-03
A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis
Mirikizumab - Ulcerative Colitis, Ulcerative Colitis Chronic
Phase 3CompletedEli Lilly and Company1722023-05-172026-06-10
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
ABX464, Placebo - Ulcerative Colitis
Phase 3CompletedAbivax S.A.6362023-01-252026-09-10
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
ABX464, Placebo - Ulcerative Colitis
Phase 3CompletedAbivax S.A.6392022-11-162026-09-10
Investigating the Anti-inflammatory Effects of Frondanol in Adults With Inflammatory Bowel Disease
Frondanol, Placebo - Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate
Phase 2 / Phase 3CompletedMohammed Bin Rashid University of Medicine and Health Sciences132022-02-192024-11-20
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)
Vedolizumab - Colitis, Ulcerative
Phase 3CompletedTakeda1212021-10-192026-04-30
A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)
Ustekinumab Dose Based on BSA and Body Weight, Matching Placebo - Colitis, Ulcerative
Phase 3CompletedJanssen Research & Development, LLC1122021-03-172026-10-20
Oral Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis in Adult Japanese Participants (ELEVATE UC 40 JAPAN)
Etrasimod, Placebo - Ulcerative Colitis
Phase 3CompletedPfizer422020-12-252023-10-16
Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis
A plant based high fiber diet that mimics fasting ("FMD") plus advanced therapy, Advanced therapy only without dietary intervention - Ulcerative Colitis
Phase 3CompletedUniversity of Miami322020-09-182025-02-28
Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis
Etrasimod, Placebo - Ulcerative Colitis
Phase 3CompletedArena Pharmaceuticals3542020-09-152022-12-21
CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC)
CT-P13 SC (Infliximab), Placebo SC - Ulcerative Colitis
Phase 3CompletedCelltrion5482020-09-012023-09-28
ENhanced Recovery in CHildren Undergoing Surgery
Perioperative surgical care - Inflammatory Bowel Disease, Crohn's Disease
Phase 3CompletedNorthwestern University5972020-07-012026-08-07
Effect of Probiotic Supplementation on the Immune System in Patients With Ulcerative Colitis in Amman, Jordan
Probiotic Formula Capsule, Placebos - Ulcerative Colitis
Phase 2 / Phase 3CompletedUniversity of Jordan302020-01-152024-09-19
Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
Etrasimod, Placebo - Ulcerative Colitis
Phase 3CompletedArena Pharmaceuticals4332019-06-132022-12-20
To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis
Ozanimod, Placebo - Colitis, Ulcerative
Phase 3CompletedCelgene1982019-06-032025-10-15
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis
Placebo, Upadacitinib - Ulcerative Colitis (UC)
Phase 3CompletedAbbVie5222018-12-062022-03-02
A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis
Mirikizumab SC, Mirikizumab IV, Placebo SC - Ulcerative Colitis
Phase 3CompletedEli Lilly and Company13282018-10-192026-05-13
An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Mirikizumab, Placebo - Ulcerative Colitis
Phase 3CompletedEli Lilly and Company12812018-06-182025-05-31
A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis
AJM300, Placebo - Colitis, Ulcerative
Phase 3CompletedEA Pharma Co., Ltd.1982018-06-062023-07-21

Showing 20 of 133. Sign in to see all of them.

Narrower conditions

Colitis, Ulcerative (123)  ·  Inflammatory Bowel Diseases (26)  ·  Crohn Disease (14)  ·  Ulcer (5)  ·  Gastrointestinal Diseases (4)  ·  Colitis, Collagenous (3)  ·  Colitis, Microscopic (3)  ·  Colonic Diseases (3)  ·  Digestive System Diseases (3)  ·  Gastroenteritis (3)  ·  Intestinal Diseases (3)  ·  Anemia (2)  ·  Anemia, Iron-Deficiency (2)  ·  Colitis, Lymphocytic (2)

Broader conditions

Colonic Diseases (130)  ·  Digestive System Diseases (130)  ·  Gastroenteritis (130)  ·  Intestinal Diseases (130)  ·  Gastrointestinal Diseases (129)  ·  Inflammatory Bowel Diseases (101)  ·  Pathological Conditions, Signs and Symptoms (11)  ·  Pathologic Processes (7)  ·  Disease Attributes (4)  ·  Behavior (3)  ·  Colitis, Microscopic (3)  ·  Health Behavior (3)  ·  Hemic and Lymphatic Diseases (3)  ·  Treatment Adherence and Compliance (3)

Interventions

Mesalamine (30)  ·  Adalimumab (12)  ·  Budesonide (11)  ·  Infliximab (6)  ·  vedolizumab (6)  ·  etrolizumab (5)  ·  mirikizumab (4)  ·  tofacitinib (4)  ·  etrasimod (3)  ·  golimumab (3)  ·  ozanimod (3)  ·  tetomilast (3)  ·  ABX464 (2)  ·  Adrenal Cortex Hormones (2)  ·  Blood Specimen Collection (2)

Sponsors

Bausch Health Americas, Inc. (13)  ·  Dr. Falk Pharma GmbH (7)  ·  Ferring Pharmaceuticals (7)  ·  Janssen Research & Development, LLC (7)  ·  Shire (7)  ·  AbbVie (6)  ·  Takeda (6)  ·  Hoffmann-La Roche (5)  ·  Pfizer (5)  ·  Warner Chilcott (5)  ·  Eli Lilly and Company (4)  ·  AbbVie (prior sponsor, Abbott) (3)  ·  Celgene (3)  ·  Centocor, Inc. (3)  ·  Otsuka Pharmaceutical Development & Commercialization, Inc. (3)

Countries

United States (82)  ·  Canada (56)  ·  Germany (54)  ·  Poland (54)  ·  Belgium (48)  ·  Hungary (47)  ·  United Kingdom (45)  ·  Czechia (44)  ·  Israel (42)  ·  Japan (38)  ·  Australia (37)  ·  France (37)  ·  Italy (36)  ·  Netherlands (35)  ·  Russia (35)

Top investigators

Arena CT.gov Administrator (2)  ·  Bruce Eric Sands (2)  ·  Bruce Sands, MD, PhD (2)  ·  Lindsey Mathew (2)

Results publications

PMID 32445184, PMID 29850873, PMID 30476584, PMID 31077827, PMID 31599001, PMID 32766762, PMID 32816215, PMID 32870265, PMID 32964215, PMID 33324993, PMID 33684552, PMID 34614208, PMID 35648151, PMID 35792493, PMID 36124702, PMID 36336750, PMID 36342120, PMID 36526796, PMID 36931693, PMID 37402275, PMID 37560161, PMID 38310565, PMID 38425446, PMID 26563167, PMID 27959607, PMID 28467869, PMID 29028981, PMID 29142515, PMID 29380251, PMID 29409871, PMID 29743836, PMID 29909019, PMID 30739254, PMID 31279870, PMID 33127596, PMID 33513294, PMID 34035832, PMID 34077627, PMID 34165201, PMID 35380664, PMID 35380740, PMID 35934286, PMID 36150926, PMID 36271912, PMID 36506749, PMID 37368103, PMID 37391056, PMID 38778549, PMID 42248437, PMID 42427284

NIH funding

2015 (8), 2004 (5), 2016 (5), 2017 (5), 2008 (3), 2018 (2), 2019 (2), 2023 (2), 2014 (1), R01HD099344 (1)